Meet the Activists
Battling the TB/HIV Epidemic Through Community Action
Through advocacy workshops and by coordinating and supporting activists' advocacy efforts, TAG and ICW work together to increase community understanding of TB/HIV coinfection and enhance research, treatment, and resources to combat the two epidemics.
Thanks to all of my activist colleagues around the world who impress and amaze me with your work every day.
-- Nelson Juma Otwoma
Nelson Juma Otwoma, Kenya
Carol has lived with HIV for many years and has also survived TB treatment. She has been able to transform this personal experience into a political campaign to address TB/HIV, and has incorporated TB advocacy into her national and global HIV activism.
Participating in the TAG-ICW advocacy trainings gave Carol a knowledge base of TB science, diagnostics, and treatment that has enabled her to train other activists on TB and TB/HIV coinfection and, along with fellow Zambian activists, to advocate for the Zambian government to implement WHO recommendations for collaborative TB/HIV activities. Carol has received global recognition for her activism and served as a panelist at the April 2008 meeting in Thailand of the UNAIDS Program Coordinating Board (PCB), addressing the issue of multidrug-resistant TB among people living with HIV. In part, her advocacy led the UNAIDS PCB to decide to monitor TB/HIV mortality numbers as a measure of the impact of the implementation of the collaborative activities recommended by the WHO policy to reduce the burden of TB/HIV. Carol was also invited to be part of the International Treatment Preparedness Coalition's World CAB meeting to discuss treatment access issues with the pharmaceutical industry. She is a community representative on the Stop TB Partnership's New Diagnostics Working Group, and is a board member representing communities of people living with TB, HIV, and malaria for UNITAID, where she has successfully lobbied for the provision of resources for diagnostics for TB drug resistance testing. For more information, please visit www.talczambia.org or e-mail Carol at email@example.com.
Coulibaly has been very active in advocating for the implementation of TB/HIV collaborative activities in his country. Through his work with Bouake Eveil, Coulibaly has provided support and education to people living with HIV and those who are coinfected, with a particular focus on the importance of TB preventive therapy among people living with HIV. His organization has successfully advocated for a more collaborative approach to fighting TB and HIV in the Bouake district and Coulibaly has also participated in some national HIV policy discussions and pushed for the inclusion of TB/HIV. Coulibaly has developed a comprehensive TB/HIV program in his organization that includes infection control measures and community TB/HIV sensitization. He has also created an association of people living with HIV and TB and their families. Because Bouake is affected by rebel activity, public health services are unstable, so Coulibaly also makes home visits to persons with HIV and TB to ensure that people have access to needed services. For more information, please e-mail Coulibaly at firstname.lastname@example.org.
Before participating in the Advocacy Project, Wim's main focus was HIV/HCV treatment advocacy for countries in the WHO European region. TAG-ICW training and support provided Wim with the tools to understand why TB is of concern for persons with HIV and strengthened his capacity to incorporate TB into his advocacy work. Wim was invited to be part of the Advocacy Project because of his role as a community representative to the Stop TB Partnership's New Drugs Working Group. He has also helped to set up a civil society network of Lusophone countries where he successfully advocated for the inclusion of TB/HIV into the network's priorities as well as into the Community of Portuguese Language Countries' health agenda. Wim gave a keynote address on community input in the regulatory process at the Global Alliance for TB Drug Development's Open Forum meeting in New Delhi in May 2008, ensured the inclusion of community perspectives in a scientific paper on priorities for new TB drug development, and provided the community perspective to the Portugal Ministry of Health on World TB Day. As chairperson of the EATG, Wim often meets with the private sector to monitor and advocate for a drug research agenda that responds to community priorities, and since his involvement with TAG and ICW Wim has incorporated TB drug development concerns in his meetings with pharmaceutical companies. For more information, please visit www.eatg.org or email Wim at email@example.com.
As an HIV treatment activist in a country with high TB/HIV prevalence, Thembi welcomed the opportunity to learn more about TB and to incorporate this knowledge into her activism. After attending advocacy workshops Thembi, through SWANNEPHA, has provided training on TB/HIV to 38 support groups and a core group of activists, and has improved SWANNEPHA's capacity to do TB/HIV advocacy and outreach. She has also helped develop a community training manual on TB/HIV and has already seen more comfort on the part of people with HIV to discuss TB within their network. Thembi has also been working on national policy advocacy to get people with HIV meaningfully integrated into TB and HIV programming and service delivery. Her national work was shared with global activists and TB/HIV implementers when she presented findings from her own and other activists' work at the 2008 PEPFAR HIV/AIDS Implementers Meeting in Uganda in June 2008. For more information, e-mail Thembi at firstname.lastname@example.org.